Profile data is unavailable for this security.
About the company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
- Revenue in USD (TTM)304.34m
- Net income in USD-450.00k
- Incorporated2010
- Employees235.00
- LocationCoherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 649-3530
- Fax+1 (302) 655-5049
- Websitehttps://www.coherus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | 0.00 | -94.05m | 121.35m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 122.33m | 75.00 | -- | 0.4386 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 122.64m | 66.00 | -- | 1.34 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 122.96m | 69.00 | -- | 1.06 | -- | 6.52 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Seres Therapeutics Inc | 64.00k | -165.29m | 124.55m | 233.00 | -- | 5.21 | -- | 1,946.13 | -1.14 | -0.2271 | 0.0004 | 0.1405 | 0.0002 | -- | -- | 274.68 | -60.50 | -41.51 | -82.15 | -54.13 | -- | -- | -258,259.40 | -170.14 | -- | -20.45 | 0.00 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Pyxis Oncology Inc | 16.15m | -57.36m | 124.88m | 54.00 | -- | 0.8124 | -- | 7.73 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 126.26m | 179.00 | -- | 0.7216 | -- | 1.90 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 126.51m | 11.00 | -- | 1.67 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 127.83m | 31.00 | -- | 2.47 | -- | 185.54 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 129.48m | 36.00 | -- | -- | -- | 2.62 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| TriSalus Life Sciences Inc | 26.89m | -58.65m | 129.85m | 112.00 | -- | -- | -- | 4.83 | -1.68 | -1.68 | 0.8963 | -0.6706 | 0.8812 | 1.23 | 6.75 | 240,098.20 | -181.70 | -- | -265.24 | -- | 87.10 | -- | -206.19 | -- | 2.00 | -26.43 | 17.43 | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 11.19m | 9.72% |
| Rubric Capital Management LPas of 30 Sep 2024 | 10.40m | 9.03% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 9.44m | 8.19% |
| Citadel Advisors LLCas of 30 Sep 2024 | 2.86m | 2.48% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.57m | 2.23% |
| Barclays Bank Plc (Private Banking)as of 30 Sep 2024 | 2.46m | 2.14% |
| Tang Capital Management LLCas of 30 Sep 2024 | 2.35m | 2.04% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.03m | 1.76% |
| CM Management LLCas of 30 Sep 2024 | 2.00m | 1.74% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 30 Sep 2024 | 1.93m | 1.67% |
